Preclinical research on the role and mechanism of MDM2 "small molecule" inhibitors combined with conventional chemo- and/or radiotherapy under normoxic and hypoxic conditions.

Targeting polo-like kinase 1 for cancer treatment: focus on combination therapy and the role of the hypoxic microenvironment.

Exploring HIF in poly(I:C)-based immunotherapy to stimulate innate immunity in glioblastoma multiforme.

Involving the innate immune system in p53-targeted combination therapies.